

**AstraZeneca – Call For Grant Applications**  
**(CGA Respiratory Severe Asthma Epithelial Alarmins Emerging Therapies 2022-01)**

<b>Submission Deadline</b>	Rolling review, with submission deadline of March 25, 2022 at 12 noon EST
<b>Primary Area of Focus</b>	Respiratory
<b>Therapeutic Area</b>	Severe asthma
<b>Need</b>	<p>Airway diseases are heterogeneous in nature, with inflammation resulting from complex, variable, and dynamic interactions between airway structural cells and the innate/adaptive immune system.</p> <p>There is increasing evidence describing the role of epithelial alarmins (including TSLP, IL-33 and IL-25) as upstream mediators/drivers of the asthma inflammatory response as well as airway hyperresponsiveness. Results of clinical trials have also elucidated the effects of targeting epithelial alarmins on the management of severe asthma.</p> <p>Patients with severe asthma need their asthma specialists and staff to be up-to-date regarding the latest advances in the pathophysiology of severe asthma, including the role of the epithelial alarmins, recent clinical trial data with emerging biologics, and the resulting implications for severe asthma management.</p>
<b>Educational Program</b>	Accredited medical education program that is being designed and implemented to engage US asthma specialists (allergist/immunologists and pulmonologists) and affiliated advance practice providers in timely, relevant, high-quality scientific/clinical content that addresses the root cause(s) of their educational and practice gaps.
<b>Budget</b>	≤ \$225,000.00
<b>Successful submission</b>	<ul style="list-style-type: none"> <li>• Independently-developed application, providing rationale for and detailed description of the goals, learning objectives, educational strategy, format, execution and measurement of program</li> <li>• Provide a summary of the healthcare and CME landscape and how the proposed program will aim to close gaps not addressed in currently available programs</li> <li>• Proposed activity(ies) will: <ul style="list-style-type: none"> <li>○ Leverage the latest digital technologies for learner engagement, including multimedia elements and learner interactivity with faculty and content</li> <li>○ Employ educational strategies for maximal retention and application of content by tailoring to the specific needs of and learning styles of the proposed audience</li> </ul> </li> <li>• Meaningful outcomes from previously executed programs with similar goal and format</li> <li>• Ability to achieve Level 4 outcomes, report monthly metrics / quarterly outcomes (broken down by specialty, profession and geography)</li> <li>• Both more traditional and novel/innovative program designs are welcome</li> </ul>
<b>CGA Code</b>	Respiratory Severe Asthma Epithelial Alarmins Emerging Therapies 2022-01
<b>Website URL</b>	<a href="https://www.astrazenecagrants.com/us-grants.html">https://www.astrazenecagrants.com/us-grants.html</a>

**Program Requirements:**

The Program must be planned and executed as an accredited activity and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and, if applicable, accreditation standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.